A previous study reported that the fusion of NAV2 and TCF7L1 is a new marker for aggressive CRC and has an important role in MYC-directed transcriptional activation and repression (Cancer Genome Atlas Network 2012). This evidence concerns the gene NAV2 and colorectal carcinoma.